• Senti Biosciences announced a strategic transaction today to spin off its Gene-Circuit-enabled pipeline, including the SENTI-202 therapy, to a newly formed private biotechnology company controlled by affiliates of Celadon, its largest investor.
  • In exchange, Senti Biosciences Holdings will receive a contingent value right (CVR) that provides its equity holders with potential milestone payments of up to $60 million over seven years.
  • The stock is trading at $0.91 (down 6.2%) today following this announcement.